Although the recent PARADISE‐MI trial (Prospective ARNI versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events after Myocardial Infarction) did not meet its primary endpoint, there was a nominally statistically significant reduction in total HF events and cardiovascular death suggesting there may be a role for sacubitril/valsartan in preventing HF after AMI, although this needs further investigation.50, 51. The gene discussed is ACE; the disease is myocardial infarction.